User login

Low Dose Abilify Ineffective as Adjunct for MDD

Augmentation of antidepressants with antipsychotics has become a common practice, and aripiprazole (Abilify) has been FDA-approved at doses from 2 mg/day to 15 mg/day for this purpose. In a recent report, 225 patients with major depressive disorder (MDD) who had failed one to four antidepressant trials were studied to determine whether low dose Abilify really works.

All editorial content is peer reviewed by the editorial board. Dr. Albucher, Dr. Balt, Dr. Gardiner, Dr. Goldberg, Dr. Lyman, Dr. Megna, Dr. Mick, Dr. Posternak, Dr. Spielmans, and Dr. Zuckerman have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity. Dr. Balt discloses that his spouse is employed as a sales representative for Otsuka America, Inc.

TCPR Continuing Education
Accredited/Approved/Accepted by:

ACCME

AMA

APA

ABPN

ANCC

Search

Search this site:

Follow Us

Drug Metabolism in Psychiatry

It's here! Click here to purchase our new book "Drug Metabolism in Psychiatry: A Clinical Guide"